reference/12253544

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12253544

Outgoing Links

Predicate	Object
contentType	Journal Article\|Meta-Analysis\|Research Support, Non-U.S. Gov't
endingPage	312
issn	1365-2141 0007-1048
issueIdentifier	3
pageRange	303-312
publicationName	British Journal of Haematology
startingPage	303
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_bcb538be81300dc8e034ad1c63fc7600
bibliographicCitation	Santos FPS, Kantarjian H, Fava C, O’Brien S, Garcia‐Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second‐generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010 Jul 12;150(3):303–12. doi: 10.1111/j.1365-2141.2010.08245.x.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8796f12e28a415774f96967e3d96504e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2179b74e09e09468d620914757116d27 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8636-1071 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8c1de7da4deb440ed2ecc8697edce38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4896-981X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e9acd5d12a5f07c295d018f941d8f94 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2fe04d613bdc20f47c425f521aa34d7e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f89be6c894deba4e08e75140e5b8bf12 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f11ea9c92dc59998ab041e02911acc0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e649c67d1fed67a6ef8e0cf5c7f7d963 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a8ab1c7498c41deaa8415f13642f5b9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a63fe78033e122238c46684f6933f743
date	2010-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1111/j.1365-2141.2010.08245.x https://pubmed.ncbi.nlm.nih.gov/20553275 https://pubmed.ncbi.nlm.nih.gov/PMC4105000
isPartOf	https://portal.issn.org/resource/ISSN/0007-1048 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1822 https://portal.issn.org/resource/ISSN/1365-2141
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Clinical impact of dose reductions and interruptions of second‐generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
discusses	http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0470497 http://id.nlm.nih.gov/mesh/M0482811 http://id.nlm.nih.gov/mesh/M0021333 http://id.nlm.nih.gov/mesh/M0017888 http://id.nlm.nih.gov/mesh/M0457532
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011505Q000037 http://id.nlm.nih.gov/mesh/D015464Q000188 http://id.nlm.nih.gov/mesh/D047428Q000008 http://id.nlm.nih.gov/mesh/D000970Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D047428Q000009 http://id.nlm.nih.gov/mesh/D013844Q000009 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D011743Q000009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D013844Q000008 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D011743Q000008 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000069439
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644241 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3062316

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129879136 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247851103

Total number of triples: 72.